98167-08-9

Basic information

• Product Name: (3R,4S,5R)-3,4,5-triacetoxycyclohex-1-ene-1-carboxylic acid
• Synonyms: (3R,4S,5R)-3,4,5-triacetoxycyclohex-1-ene-1-carboxylic acid
• CAS NO: 98167-08-9
• Molecular Weight: 300.265
• Mol File: 98167-08-9.mol

Chemical Properties

• CAS DataBase Reference: (3R,4S,5R)-3,4,5-triacetoxycyclohex-1-ene-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S,5R)-3,4,5-triacetoxycyclohex-1-ene-1-carboxylic acid(98167-08-9)
• EPA Substance Registry System: (3R,4S,5R)-3,4,5-triacetoxycyclohex-1-ene-1-carboxylic acid(98167-08-9)

Safety Data

• Hazardous Substances Data: 98167-08-9(Hazardous Substances Data)

Upstream product

• 138-59-0 shikimic acid 
• 108-24-7 acetic anhydride 
• 108-22-5 Isopropenyl acetate 
• 64780-68-3 (1R)-3c,4c,5t-triacetoxy-1-acetoxymethyl-cyclohexan-r-ol 
• 101500-07-6 (3R)-3r,4c,5t-triacetoxy-1-acetoxymethyl-cyclohexene 

Downstream Products

• 134252-22-5 3,4,5-tri-O-acetyl shikimate d'ethyle 
• 134252-25-8 3,4,5-tri-O-acetyl shikimate de (2,6-di-t-butyl-4-methyl)phenyle 

Relevant articles and documents

Protection of COOH and OH groups in acid, base and salt free reactions

We report an iron-catalyzed general functional group protection method with inexpensive reagents. This environmentally benign process does not use acids or bases, and does not produce waste products. Further purification beyond filtration and evaporation is, in most cases, unnecessary. Free COOH and OH groups can be protected in a one-pot reaction.

ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS

Disclosed herein are acylated active agents (e.g., acylated catechin polyphenols, acylated carotenoids, acylated mesalamines, acylated sugars, acylated shikimic acids, acylated ellagic acid, acylated ellagic acid analogue, and acylated hydroxybenzoic acids), active agent combinations (e.g., with a second agent that is a fatty acid) and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

New aspects of the Hunsdiecker-Barton halodecarboxylation-syntheses of phospha-shikimic acid and derivatives

We report an efficient synthetic approach to phospha-isosteres of important intermediates of the shikimic acid pathway by the application of the Hunsdiecker-Barton halodecarboxylation to cyclohexenylcarboxylic acids. As examples, phospha-shikimic acid, it

Cationic amphiphile with shikimic acid headgroup shows more systemic promise than its mannosyl analogue as DNA vaccine carrier in dendritic cell based genetic immunization

Mannosylated cationic vectors have been previously used for delivering DNA vaccines to antigen presenting cells (APCs) via mannose receptors expressed on the cell surface of APCs. Here we show that cationic amphiphiles containing mannose-mimicking quinic